PacBio Reports Flat Revenue Amid Strategic Shifts and Rising Costs — Pacific Biosciences of California, Inc.

Event summary

PacBio reported $39.0 million in revenue for Q2 2026, down slightly from $39.8 million in Q2 2025.
Non-GAAP gross margin declined to 36% from 38%, driven by higher compute and memory costs, Vega manufacturing transition costs, and lower Revio average selling prices.
The company placed 20 Revio systems and 26 Vega systems in Q2 2026, compared to 15 Revio and 38 Vega placements in the same period last year.
PacBio commenced global commercial rollout of SPRQ-Nx chemistry, offering whole genome sequencing at $345 per genome with enhanced methylation detection and DeepConsensus AI algorithm.
The company implemented restructuring actions to streamline marketing and R&D organizations and strengthen its go-to-market commercial organization.

The big picture

PacBio's Q2 2026 results reflect the challenges of balancing strategic investments in new technologies with cost management. The company's focus on long-read sequencing and AI-powered consensus algorithms positions it in a competitive genomics market, but declining margins and system placements signal potential execution risks. The broader industry trend towards population-scale genomic programs presents both opportunities and pressures for PacBio to differentiate its offerings.

What we're watching

Revenue Growth: Whether PacBio can sustain revenue growth amid declining instrument placements and rising costs.
Cost Management: The effectiveness of PacBio's restructuring efforts in controlling operating expenses and improving gross margins.
Product Adoption: The pace at which the SPRQ-Nx chemistry is adopted by population-scale customers and its impact on consumables revenue.